All In Biotech

Drug Trial Radar · NCT01194414

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

A Randomized, Double-blind, Parallel Group Study of the Safety and Effect on Clinical Outcome of Tocilizumab SC Versus Tocilizumab IV, in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs), in Patients With Moderate to Severe Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Jun 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,262 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,262

Actual

Start

Sep 2010

Primary completion

Jan 2012

Study completion Aug 2013

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 3, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis. Participants were randomized to receive either tocilizumab 162 mg sc weekly plus iv placebo every 4 weeks, or tocilizumab 8 mg/kg iv every 4 weeks plus sc placebo weekly during the double-blind period from baseline to Week 24. The double-blind period was followed by a 72-week open-label treatment with some switching of sc and iv administration. No placebo was administered in the open-label phase. Participants continued on their stable dose of disease-modifying antirheumatic drugs (DMARDs) throughout the study. Anticipated time on study treatment was 2 years.

Conditions

  • Rheumatoid Arthritis

Interventions

  • tocilizumab SCDrug

    Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.

  • tocilizumab IVDrug

    Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.

  • placebo to tocilizumab SCDrug

    Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.

  • placebo to tocilizumab IVDrug

    Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.

  • Disease-modifying antirheumatic drugs (DMARDs)Drug

    stable dose as prescribed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving an American College of Rheumatology Criteria (ACR20) Response at Week 24Time frame: Baseline, 24 weeks
  2. Percentage of Participants With Adverse Events, Serious Adverse Events and Clinically Significant Laboratory AssessmentsTime frame: Baseline to up to 3 months after last dose of study drug (approximately up to 2 years)

Locations

216 sites in 26 countries. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Tucson, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Upland, California

  • Site not named

    Van Nuys, California

  • Site not named

    Denver, Colorado

  • Site not named

    Bridgeport, Connecticut

  • Site not named

    Delray Beach, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    Pinellas Park, Florida

  • Site not named

    South Miami, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Morton Grove, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    Monroe, Louisiana

  • Site not named

    Petoskey, Michigan

  • Site not named

    Saint Claire Shores, Michigan

  • Site not named

    Eagan, Minnesota

  • Site not named

    Florissant, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Clifton, New Jersey

  • Site not named

    Manalapan, New Jersey

  • Site not named

    Voorhees Township, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Binghamton, New York

  • Site not named

    Orchard Park, New York

  • Site not named

    Asheville, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Wilmington, North Carolina

  • Site not named

    Cincinnati, Ohio

Showing 40 of 216 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.